Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Denosumab Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Osteoporosis Agents: Xgeva (denosumab) and Denosumab Biosimilars

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit prior authorization for denosumab products for MassHealth members, including prevention of skeletal-related events associated with bone metastases or multiple myeloma, treatment of hypercalcemia of malignancy, and treatment of giant cell tumor of bone.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyOsteoporosis Agents: Xgeva (denosumab) and Denosumab Biosimilars
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateJan 4, 202748d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization under the MassHealth UPPL for medical-benefit requests and document required preferred-biosimilar trials when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    Jubereq (denosumab-desu) was added as an additional preferred denosumab biosimilar.

    Jubereq prior authorization requirements were added for both the pharmacy and medical benefits, and preferred-biosimilar criteria were updated.

    Continuation criteria were updated to reflect MassHealth stability requirements.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8Denosumab products listed
    3Covered indication categories
    3Preferred biosimilars required
    1 yearAuthorization duration
    90 daysNew-plan documentation window

    Coverage Criteria

    Initial authorization framework

    Authorization may be granted through one of the following pathways:

    New-plan continuation or initial covered indication

    • New-plan current treatment: The member's coverage effective date is less than or equal to 90 days, and medical records document that the member is currently receiving treatment with the requested drug.<= 90 days

      Treatment obtained as samples or through a manufacturer's patient assistance program does not establish current treatment.

    • Initial authorization requirements: The member has an eligible indication, the prescriber meets the specialty requirement or has provided specialist consultation notes, dosing is appropriate according to FDA labeling, and any applicable preferred-biosimilar requirements are met.

    Skeletal-related events and hypercalcemia

    Covered when the diagnosis is one of the following and all applicable additional requirements are met:

    Eligible oncology indications

    • Prevention of skeletal-related events secondary to bone metastases in cancer related to solid tumors.
    • Prevention of skeletal-related events secondary to multiple myeloma.
    • Treatment of hypercalcemia of malignancy.

    Oncology prescriber and dosing requirements

    For the eligible oncology indications, all of the following are required:

    Additional oncology requirements

    • The prescriber is an oncologist, hematologist, or orthopedic specialist, or has provided consultation notes from an oncologist, hematologist, or orthopedic specialist.
    • Dosing is appropriate according to FDA labeling.
    • Applicable non-preferred-agent requirements: For Aukelso, Bomyntra, Osenvelt, Wyost, or Xgeva, the member has had an inadequate response, adverse reaction, or contraindication to all of Bilprevda, Jubereq, and Xtrenbo, and the prescriber provides clinical rationale explaining why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents.

    Giant cell tumor of bone

    Covered when all of the following are met:

    GCTB diagnosis and treatment eligibility

    • Diagnosis of giant cell tumor of the bone (GCTB).
    • ONE of the following surgical-status criteria

      • The tumor or metastases are unresectable.
      • Surgical resection is likely to result in severe morbidity.
      • Surgery is not an option at this time.
    • Dosing is appropriate according to FDA labeling.

    Continuation therapy

    Continuation authorization may be granted when one of the following pathways is met:

    Continuation pathways

    • Resubmission by the prescriber will infer positive response to therapy.
    • Bilprevda and Xtrenbo stabilization

      • The member is stabilized on Bilprevda and Xtrenbo.
      • Medical records document that the member remains at high risk for fracture or has a clinical picture suggesting high risk for fracture.
    • Other denosumab stabilization

      • The member is stabilized on Xgeva or another denosumab biosimilar, except Bilprevda and Xtrenbo.

    Initial Therapy

    Initial therapy

    Initial authorization may be granted for an eligible indication when all applicable criteria are met:

    Initial denosumab authorization

    • Eligible indication

      • Prevention of skeletal-related events secondary to bone metastases in cancer related to solid tumors.
      • Prevention of skeletal-related events secondary to bone metastases in multiple myeloma.
      • Treatment of hypercalcemia of malignancy.
      • Treatment of giant cell tumor of the bone when the tumor or metastases are unresectable, surgical resection is likely to result in severe morbidity, or surgery is not an option at this time.

    Continuation Therapy

    Denosumab continuation

    Continuation authorization may be granted when one of the following is met:

    Continuation criteria

    • Resubmission by the prescriber will infer positive response to therapy.
    • Preferred-product stabilization

      • The member is stabilized on Bilprevda and Xtrenbo.
      • Medical records document that the member remains at high risk for fracture or has a clinical picture suggesting high risk for fracture.
    • Non-preferred-product stabilization

    Provider Requirements and Denial Risks

    Prior Authorization

    Medical Benefit Prior Authorization Required

    Prior authorization is required for these products when billed under the medical benefit. The medications are also available through the pharmacy benefit; verify pharmacy-benefit coverage and criteria in the MassHealth Drug List.

    • Medical benefit PA: 833-895-2611; fax 888-656-6671.
    • Pharmacy benefit: 800-711-4555; fax 844-403-1029.
    • Products include Xgeva (denosumab), Aukelso, Bilprevda, Bomyntra, Jubereq, Osenvelt, Wyost, and Xtrenbo.
    Step Therapy

    Preferred Denosumab Biosimilars

    For Aukelso, Bomyntra, Osenvelt, Wyost, or Xgeva, document inadequate response, adverse reaction, or contraindication to all required preferred denosumab biosimilars before requesting the non-preferred agent.

    • Required preferred-agent history: Bilprevda (denosumab-nxxp), Jubereq (denosumab-desu), and Xtrenbo (denosumab-qbde).

    Clinical Background

    Xgeva (denosumab) and the listed denosumab biosimilars are monoclonal antibody therapies used in oncology-related bone disease. The policy addresses prevention of skeletal-related events associated with bone metastases from solid tumors or multiple myeloma, treatment of hypercalcemia of malignancy, and treatment of giant cell tumor of bone when the tumor is unresectable, resection is likely to result in severe morbidity, or surgery is not an option at the time of treatment.

    Definitions

    Skeletal-related events (SREs)
    DefinitionSkeletal-related events associated with bone metastases in patients with solid tumors or multiple myeloma.
    Associated conditionBone metastases from solid tumors or multiple myeloma.
    Policy relevanceXgeva (denosumab) is approved for prevention of SREs in these patient populations.
    Giant cell tumor of bone (GCTB)
    DefinitionGiant cell tumor of bone (GCTB) in adults and skeletally mature adolescents.
    Unresectable diseaseThe tumor or metastases are unresectable.
    Severe morbidity

    Preferred-Agent Requirements

    StepRequested productsPreferred-agent requirementAdditional documentation
    1Aukelso (denosumab-kyqq), Bomyntra (denosumab-bnht), Osenvelt (denosumab-bmwo), Wyost (denosumab-bbdz), or Xgeva (denosumab)Inadequate response, adverse reaction, or contraindication to all three preferred biosimilars: Bilprevda (denosumab-nxxp), Jubereq (denosumab-desu), and Xtrenbo (denosumab-qbde).Provide clinical rationale explaining why the requested non-preferred agent is expected to produce a different clinical outcome than the preferred agents.

    Denosumab Biosimilars

    Billing Rule

    Xgeva: preferred denosumab product

    Xgeva (denosumab) is a preferred denosumab biosimilar product and is one of the products required in the preferred-agent trial requirement for specified non-preferred agents.

    Billing Rule

    Xgeva: additional preferred-agent pathway

    Xgeva (denosumab) is an additional preferred denosumab biosimilar product and is one of the products required in the preferred-agent trial requirement for specified non-preferred agents.

    Billing Rule

    Xgeva: preferred step-through product

    Xgeva (denosumab) is a preferred denosumab biosimilar and a step-through product. It is one of the products required in the preferred-agent trial requirement for specified non-preferred agents.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyOsteoporosis Agents: Xgeva (denosumab) and Denosumab Biosimilars
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateJan 4, 202748d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization under the MassHealth UPPL for medical-benefit requests and document required preferred-biosimilar trials when applicable.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation TherapyProvider Requirements and Denial RisksClinical BackgroundDefinitionsPreferred-Agent RequirementsDenosumab Biosimilars
    Applicable non-preferred-agent requirements: For Aukelso, Bomyntra, Osenvelt, Wyost, or Xgeva, the member has had an inadequate response, adverse reaction, or contraindication to all of Bilprevda, Jubereq, and Xtrenbo, and the prescriber provides clinical rationale explaining why the requested non-preferred agent is expected to provide a different clinical outcome than the preferred agents.
    Medical records document that the member remains at high risk for fracture or has a clinical picture suggesting high risk for fracture.
  1. Clinical rationale is provided for using the requested agent instead of Bilprevda and Xtrenbo.
  2. The prescriber is an oncologist, hematologist, or orthopedic specialist, or has provided consultation notes from one of those specialists.
  3. Dosing is appropriate according to FDA labeling.
  4. Applicable preferred-biosimilar requirements: For Aukelso, Bomyntra, Osenvelt, Wyost, or Xgeva, the member has had an inadequate response, adverse reaction, or contraindication to all of Bilprevda, Jubereq, and Xtrenbo, and the prescriber provides clinical rationale explaining why the requested agent is expected to provide a different clinical outcome than the preferred agents.
  5. The member is stabilized on Xgeva or another denosumab biosimilar, except Bilprevda and Xtrenbo.
  6. Medical records document that the member remains at high risk for fracture or has a clinical picture suggesting high risk for fracture.
  7. Clinical rationale is provided for using the requested agent instead of Bilprevda and Xtrenbo.
  8. The requirement applies to requests for prevention of skeletal-related events, treatment of hypercalcemia of malignancy, and GCTB.
  9. Documentation Required

    Current-Treatment Records for New Members

    If the member has been enrolled in the plan for 90 days or less, submit medical records showing that the member is currently receiving the requested drug. This requirement does not apply when the product was obtained as samples or through a manufacturer patient assistance program.

    • Use the member’s coverage effective date to establish the new-plan window.
    • Records should support active treatment with the requested product.
    Documentation Required

    Initial Authorization Documentation

    For an initial authorization, submit the applicable diagnosis, the prescriber’s specialty or specialist consultation documentation, confirmation that treatment is appropriate, and supporting clinical records. Dosing must be consistent with FDA labeling.

    • Covered diagnoses include prevention of skeletal-related events from bone metastases related to solid tumors, prevention of skeletal-related events in multiple myeloma, treatment of hypercalcemia of malignancy, and giant cell tumor of the bone (GCTB).
    • Include records supporting the diagnosis and the requested treatment.
    Documentation Required

    Non-Preferred Agent Documentation

    When requesting Aukelso, Bomyntra, Osenvelt, Wyost, or Xgeva, document inadequate response, adverse reaction, or contraindication to each required preferred agent and explain why the requested non-preferred agent is expected to produce a different clinical outcome.

    • Document the applicable reason for each of Bilprevda, Jubereq, and Xtrenbo.
    • Provide a clinical rationale specific to the requested non-preferred product.
    Documentation Required

    Continuation Documentation

    For continuation authorization, the prescriber’s resubmission will infer positive response to therapy. Submit records showing that the member remains at high risk for fracture or has a clinical picture suggesting high fracture risk, with additional rationale when switching from certain denosumab products.

    • If stabilized on Bilprevda and Xtrenbo, submit records documenting ongoing high fracture risk or a clinical picture suggesting high fracture risk.
    • If stabilized on Xgeva or another denosumab biosimilar other than Bilprevda and Xtrenbo, submit ongoing-risk records and the rationale for using the requested agent instead of Bilprevda and Xtrenbo.
    • Authorizations are granted for 1 year.
    Denial Risk

    Non-Covered Indication

    Coverage is limited to the policy’s covered indications. Requests for uses outside those indications may be denied.

    • Prevention of skeletal-related events secondary to bone metastases in solid tumors.
    • Prevention of skeletal-related events secondary to multiple myeloma.
    • Treatment of hypercalcemia of malignancy.
    • Treatment of GCTB when the applicable surgical-eligibility criteria are met.
    Denial Risk

    Preferred Biosimilar Requirement

    A request for Aukelso, Bomyntra, Osenvelt, Wyost, or Xgeva may be denied when the required history with all preferred agents is absent or not adequately documented.

    • Document inadequate response, adverse reaction, or contraindication to Bilprevda, Jubereq, and Xtrenbo.
    • Include clinical rationale explaining why the requested agent is expected to provide a different clinical outcome.
    Denial Risk

    Specialist and Dosing Requirements

    The prescriber must be an oncologist, hematologist, or orthopedic specialist, or provide consultation notes from one of these specialists. Requested dosing must be appropriate under FDA labeling.

    • Missing specialty eligibility or required consultation documentation may result in denial.
    • Dosing that is inconsistent with FDA labeling may result in denial.
    Denial Risk

    GCTB Surgical Eligibility

    For GCTB, document the diagnosis and show that surgery is not an appropriate alternative at the time of treatment. Coverage may be denied when surgical resection is feasible without severe morbidity.

    • The tumor or metastases must be unresectable; or
    • Surgical resection is likely to result in severe morbidity; or
    • Surgery is not an option at this time.
    Surgical resection is likely to result in severe morbidity.
    Surgery not availableSurgery is not an option at the time of treatment.